Brief: Anebulo Pharmaceuticals To Announce Topline Data For Aneb-001 From An Ongoing Phase 2 Clinical Trial For Acute Cannabinoid Intoxication On Tuesday July 5, 2022
23/06/2022 21:00
June 23 (Reuters) - Anebulo Pharmaceuticals Inc ANEB.O :
* ANEBULO PHARMACEUTICALS TO ANNOUNCE TOPLINE DATA FOR
ANEB-001
FROM AN ONGOING PHASE 2 CLINICAL TRIAL FOR ACUTE CANNABINOID
INTOXICATION ON TUESDAY JULY 5, 2022
Source text for Eikon: ID:nBw9vJ4sHa
Further company coverage: ANEB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Anebulo Pharmaceuticals
See all newsAdvisory: Dated alert on Anebulo Pharmaceuticals' voluntary delisting from Nasdaq withdrawn
Anebulo Pharmaceuticals Q2 net loss narrows
Brief: Anebulo Pharmaceuticals Announces Intention To Voluntarily Delist From Nasdaq And Deregister With SEC
Anebulo Pharmaceuticals posts Q1 net loss
Brief: Anebulo Pharmaceuticals Reports Fourth Quarter And Fiscal Year 2025 Financial Results